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Abstract Background and aim: Some studies recently reported a favourable effect for cis-9,
trans-11 conjugated linoleic acid (CLA) on plasma lipoprotein profile of healthy subjects. Aim
of this crossover intervention study was to evaluate the influence of a short-term dietary
intake of a cheese derived from sheep’s milk naturally rich in CLA on several atherosclerotic
biomarkers, in comparison with a commercially available cheese.
Methods and results: Ten subjects (6 F; 4 M) with a median age of 51.5 followed for 10 weeks
a diet containing 200 g/week of cheese naturally rich in CLA (intervention period) and for the
same period a diet containing a commercially available cheese of the same quantity (placebo
period). Consumption of the dairy product naturally rich in cis-9, trans-11 CLA determined
a significant (p< 0.05) reduction in inflammatory parameters such as interleukin-6 (pre:
8.08  1.57 vs. post: 4.58  0.94 pg/mL), interleukin-8 (pre: 45.02  5.82 vs. post:
28.59  2.64 pg/mL), and tumour necrosis factor-a (pre: 53.58  25.67 vs. post:
32.09 17.42 pg/mL) whereas no significant differences in the placebo period were observed.
With regard to haemorheological parameters, the test period significantly ameliorated eryth-
rocytes’ filtration rate (pre: 7.61 0.71% vs. post: 9.12 0.97%; pZ 0.03) with respect to the
placebo period. Moreover, a reduction in the extent of platelet aggregation, induced by
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arachidonic acid [pre: 87.8 1.76% vs. post: 77.7 3.56%; pZ 0.04] was observed during the
test period in comparison with the placebo period.
Conclusions: Dietary short-term intake of the tested dairy product naturally rich in cis-9,
trans-11 CLA appeared to cause favourable biochemical changes of atherosclerotic markers.
ª 2009 Elsevier B.V. All rights reserved.
Introduction
Conjugated linoleic acid (CLA) is a mixture of linoleic acid
isomers with conjugated double bonds [1]. This poly-
unsaturated fatty acid is produced naturally in the rumen of
ruminant animals and can be found in foods derived from
ruminant sources. Indeed, the major dietary source of CLA
for humans is meat, fat, milk and dairy products of rumi-
nant animals [1e3]. Recent studies showed beneficial
effects of an isomer of CLA, the cis-9, trans-11, that
accounts for as much as 85e90% of the total CLA content
in food products, on neoplastic and atherosclerotic
processes, as well as on immune function and modulation of
body composition [4e6]. To date, the contribution of CLA to
the human diet is relatively small; thus, over the years
growing interest in the potential for naturally increasing the
isomer cis-9, trans-11 CLA content of milk and dairy prod-
ucts has been reported [7]. Up to now, however, relatively
little information from dietary intervention studies with
CLA-enriched dairy products in humans is available.
Aim of this crossover intervention study was to investi-
gate the effect of consumption of a sheep cheese naturally
rich in cis-9, trans-11 CLA compared to the effect of
a commercially available cheese on lipid parameters,
inflammatory cytokines, haemorheological variables and
platelet function of clinically healthy subjects.
Methods
Study population
Ten clinically healthy subjects (6 F; 4 M; mean age: 45.6
years) were recruited. Subjects taking any prescribed
medications, food supplements, or following special diets
were excluded from the study. Participants were subjects
who reported being fond of cheese and willing to undertake
a cheese consumption period. In order to identify symptom-
free subjects and to exclude who were suspected of having
any form of vascular and inflammatory diseases, a detailed
interview addressed to personal and familial history was per-
formed.Current smoking statuswasdeterminedat the timeof
physicalexamination.Bodymass index (BMI)wascalculatedas
weight (kg)/height (m)2. All participants gave signed informed
consent; the study was approved by the local Ethics
Committee and applies with the Declaration of Helsinki.
Cheese characteristics
Pecorino Toscano and placebo cheeses were commercial
products and they were bought together in a store. These
two cheeses were ripened respectively at 90 and 160 days,
as suggested by disciplinary of production.
Ether extract and crude protein content of the two
cheeses were determined according to the Association of
Official Analytical Chemists [8]. Pecorino cheese showed
a significantly higher content of crude protein and ether
extract with respect to placebo cheese (pecorino: 39.0 and
32.5 g/100 g of dry vs. placebo cheese 27 g and 28 g;
p< 0.05 for all).
Cheese fat, for fatty acid profile, was extracted
according to Folch et al. [9]. The fatty acid methyl esters
(FAME) were prepared with a base catalyzed trans-esteri-
fication according to Christie [10]. The FAME were sepa-
rated on GC equipped with a capillary column (CP-Select CB
for FAME Varian, Middelburg, The Netherlands:
100 m 0.25 mm i.d.; film thickness 0.20 mm) and quanti-
fied using nonadecanoic acid (C19:0), methyl ester (Sigma
Chemical Co., St. Louis, MO) as the internal standard. The
injector and flame ionization detector temperatures were
respectively 270 C and 300 C. The programmed temper-
ature was 40 C for 4 min, increased to 120 C at a rate of
10 C/min, maintained at 120 C for 1 min, increased to
180 C at a rate of 5 C/min, maintained at 180 C for
18 min, increased to 200 C at a rate of 2 C/min, main-
tained at 200 C for 1 min, increased to 230 C at a rate of
2 C/min and maintained at this last temperature for
19 min. The split ratio was 1:100 and helium was the carrier
gas with a flux of 1 mL/min. Individual FAME were identified
by comparison of the relative retention times of FAME
peaks from samples, with those of the standard mixture 37
Component FAME Mix (Supelco, Bellefonte, PA). Individual
trans-9 C18:1, trans-11 C18:1, trans-12 C18:1, trans-13
C18:1 (Supelco), individual cis-9, trans-11 and trans-10, cis-
12 CLA (Matreya Inc.), CLA mix standard (Sigma Chemical
Co) and published isomeric profile [11,12] were used to
identify trans-C18:1 and CLA isomers of interest. Non-
adecanoic acid was used as an internal standard to avoid
overestimation biases that can arise when results are
expressed as a relative percentage of the area of analysed
peaks (since areas of small peaks are not included). Since
all methods using peak normalization and expressing results
in relative percentage of the area of analysed peaks are
subjected to an over-evaluation, because areas of small
peaks are not considered, the problem was avoided using
nonadecanoic acid as the internal standard. All results
concerning the fatty acid composition are expressed as g/
100 g of lipids. The fatty acid profile of the two cheeses is
shown in Table 1.
Experimental design
The study had a crossover design. Before starting, a run-in
period (i.e. a period when the clinical trial has begun but
the dietary intervention has not started) for all the subjects
was performed. After that period, all participants were
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instructed to undertake a 10-week study period (interven-
tion period ) with about 2 kg of the test cheese (200 g/
week). An expert dietician gave specific dietary recom-
mendations to consume cheese three times per week by
maintaining a regular eating pattern during the interven-
tion period, except for cheese intake. The amount of
cheese to be consumed was provided at the end of the
physical examination to each participant, in weighed
portion size at no cost. Thereafter, a washout period (i.e.
a period when subjects were instructed not to consume any
type of cheeses) of 10 weeks was followed by all the
subjects (washout period ). For the next 10 weeks of the
study (control period ) a commercially available cow
cheese of the same quantity of the test cheese was given to
all the subjects. Fasting blood samples were obtained at
the beginning and at the end of each period.
Blood measurements
Venous blood samples anticoagulated with 0.129 M sodium
citrate (ratio 9:1) were collected from the antecubital vein
into evacuated plastic tubes (Vacutainer), after an over-
night fasting. Whole venous blood was also collected in
tubes without anticoagulant. Citrated and serum samples
were centrifuged at 2000 g for 10 min at 4 C, and super-
natants were stored in aliquots at 80 C until assays. Lipid
variables were assessed by conventional methods. Inter-
leukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10),
interleukin-12 (IL-12), tumour necrosis factor-a (TNF-a) and
vascular endothelial growth factor (VEGF) levels were
determined by using the Bio-Plex cytokine assay (Bio-Rad
Laboratories Inc., Hercules, CA, USA), according to manu-
facturer’s instructions.
With regard to haemorheological variables, whole blood
viscosity (WBV) and plasma viscosity (PLV) were measured
using the rotational viscosimeter LS 30 (Contraves, Zurich,
Switzerland), whereas erythrocytes’ filtration was
measured by a microcomputer-assisted filtrometer, model
MF4 (Myrenne GmbH, Roetgen, Germany). Erythrocyte
deformability index (DI) was estimated by a curve indi-
cating erythrocyte filtration throughout a 10 min recording
in order to determine rheological properties of erythro-
cytes, passing them through polycarbonate filters with
5-mm micropores (Nucleopore, Pleasanton, CA, USA). The
initial flow rate from the microcomputer-generated curves
was used for assessing erythrocyte DI. WBV was analysed at
shear rates of 0.512 s1 and 94.5 s1.
For platelet aggregation assays whole blood specimens
were centrifuged for 10 min at 250 g to obtain platelet-rich
plasma. Afterwards, platelet-rich plasma was stimulated
with 2 and 10 mM ADP (Mascia Brunelli, Milan, Italy) and
with 1 mM arachidonic acid (Sigma-Aldrich, Milan, Italy)
using an APACT 4 aggregometer (Helena Laboratories Italia
s.p.a., Milan, Italy). The coefficient of variation of arach-
idonic acid and ADP platelet aggregations were 5.8% and
6.8%, respectively.
Statistical analysis
Statistical analysis was performed by using the SPSS
(Statistical Package for Social Sciences Inc., Chicago, IL,
USA) software for Windows (Version 13.0). Results are
expressed either as mean standard deviation (SD) or as
median and range, as appropriate. All data referable to
the single different treatments were analysed by means
of the one-way ANOVA, keeping the factor ‘‘diet’’ as the
fixed one. The analyses were simplified by calculating the
absolute change for each variable tested (mean value at
baseline subtracted from the mean value after interven-
tion for each subject) with independent t sample tests.
No carry-over effect was observed. Therefore, all data
were treated as paired samples from a crossover study.
Data that were not normally distributed were logarith-
mically transformed or analysed by the nonparametric
Wilcoxon signed-ranked test. Data were analysed by
using paired t tests for significant differences between
changes observed during test and control intervention
periods. Moreover, in order to compare the effect of test
cheese compared to baseline and to the placebo cheese
a general linear model for repeated measurements,
after adjustment for age and gender, was performed. A
p-value< 0.05 was considered to indicate statistical
significance.







C8 2.02 1.14 <0.05
C10 6.32 2.80 <0.05
C12 3.71 3.87 n.s.
C14 8.58 11.82 <0.05
C14:1 0.12 0.28 <0.05
C15 0.94 1.00 n.s.
C16 17.53 32.56 <0.05
C16:1n7 0.86 1.53 <0.05
C17 0.46 0.47 n.s.




C18:1 trans-9 0.25 0.31 <0.05
C18:1 trans-10 0.43 0.19 <0.05
C18:1 trans-11 3.28 0.40 <0.05
C18:1 cis-9 14.65 15.44 <0.05
C18:1 cis-11 0.26 0.28 n.s.
C18:1 cis-12 0.09 0.16 n.s.
C18:2n-6 trans 0.12 0.09 n.s.
C18:2n-6 cis 0.92 1.84 <0.05
C18:3n-6 0.05 0.11 <0.05
C18:3n3 0.62 0.43 <0.05
C20 0.15 0.19 n.s.
cla cis-9, trans-11 1.56 0.19 <0.05
C18:4n3 0.04 0.05 n.s.
C21 0.06 0.07 n.s.
C20:4n6 0.06 0.05 n.s.
C20:5n3 0.06 0.03 n.s.
C23 0.03 0.02 n.s.
C24 0.03 0.01 n.s.
C24:1 0.01 0.01 n.s.
C22:6n3 0.03 0.02 n.s.
n.s. not significant.
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Results
Baseline and demographic characteristics of the subjects
enrolled in the study are shown in Table 2. The median age
of the study population was 51.5 years (range: 30e65).
Three subjects were current smokers. There were no
significant differences for age, body mass index, and lipid
variables between males and females.
Changes of parameters investigated after the 2 different
dietary interventions were measured by using a general
linear model for repeated measurements. At a model
adjusted for age and gender lipid variables (total, LDL, and
HDL cholesterols, triglycerides) showed no significant
changes during either intervention phases (Table 3).
On the contrary, the intervention period determined
significant decreases for inflammatory cytokines (Table 4).
Indeed, the study participants reported significant changes
of interleukin-6 (43.2%), interleukin-8 (36.5%), and
tumour necrosis factor-alpha (40.1%) levels during the
test period compared to the control period.
Haemorheological variables were also investigated
before and after the two different dietary interventions
(Table 5). After adjustment for age, gender, DI resulted to
be significantly improved at the end of the intervention
period, whereas no significant changes during the control
period were observed. In addition, changes in PLV during
the intervention period resulted to be significantly
different from those observed during the control period.
Finally, platelet aggregation induced by different
agonists at different concentrations was also investigated
in relation to the two dietary interventions (Table 6). At the
end of the intervention period a significant reduction of
platelet aggregation induced by arachidonic acid was
observed, whereas no changes during the control period
were reported.
Discussion
The present study examined the effects of a natural cis-9,
trans-11 CLA-rich ewe cheese on several human health
parameters. Main findings were the significant reductions of
inflammatory cytokines, rheological parameters and
platelet aggregation profile during the dietary intervention
with CLA-rich cheese compared to a dietary intervention
with a commercially available cow cheese. Indeed, dietary
intervention with pecorino cheese obtained by milk of ewes
fed with a grass naturally rich in cis-9, trans-11 CLA
determined a consistent reduction of inflammatory cyto-
kines, a relevant improvement of rheological conditions of
blood, and a substantial reduction of platelet aggregation






Age, yearsa 53 (30e65) 56 (30e63) 0.09
BMI, kg/m2 24.8 4.2 25.2 3.8 0.8
Smoking habit, n (%) 1 (25) 2 (33.3) 0.8
Total cholesterol, mg/dL 176.2 17.4 195.7 32.7 0.4
LDL-cholesterol, mg/dL 97.5 16.2 111 26.8 0.6
Triglycerides, mg/dL 75 11.5 89.7 22.2 0.5
BMI, Body Mass Index; LDL, Low-Density Lipoprotein.
a Median and (range).
Table 3 Effect of dietary interventions with CLA-rich and control dairy products on lipid profile
Variable Test period Control period pa
Total cholesterol, mg/dL
Before 187.9 8.3 195.7 9.79
After 189.2 11.9 195.7 7.08
p (beforeeafter) 0.9 0.1
Change 1.3 (17.42; 20.02) 0 (25.8; 25.8) 0.8
LDL-cholesterol, mg/dL
Before 105.6 7.39 123.6 9.02
After 116.2 8.89 127.5 7.01
p (beforeeafter) 0.06 0.6
Change 10.6 (0.35; 21.55) 3.87 (15.55; 23.31) 0.7
HDL-cholesterol, mg/dL
Before 64.2 4.24 56.3 3.14
After 53.7 3.04 52.1 2.54
p (beforeeafter) 0.09 0.2
Change 10.5 (23.21; 2.26) 4.12 (10.87; 2.62) 0.4
Triglycerides, mg/dL
Before 75.8 14.87 79.88 11.1
After 85.8 21.29 80.75 7.06
p (beforeeafter) 0.08 0.7
Change 10 (6.52; 26.52) 0.87 (25.19; 26.95) 0.7
LDL: Low-Density Lipoprotein; HDL: High-Density Lipoprotein.
General linear model adjusted for age, and gender; values are expressed as geometric mean and SD.
a Comparison between absolute changes induced by the 2 diets (Wilcoxon signed-ranks test).
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induced by arachidonic acid. All these modifications were
not observed in the control period of dietary intervention
with a commercially available cow cheese, so resulting in
a significant difference between the test ewe cheese and
the cow cheese in terms of reduction of the global risk of
cardiovascular diseases. Actually, sheep cheese is naturally
rich in CLA because it is made with milk from grazing ewes.
In fact, it is well known from the literature that it is
possible to manipulate the fatty acid profile of sheep dairy
products, in a higher extent than that of the cows, to
maximize the content of beneficial fatty acids by the use of
appropriate fresh forage-based regimens [13].
CLA has been recently reported to have antiatherogenic
and antineoplastic properties [4e6]. In particular, one of
the CLA isomer, the cis-9, trans-11, has been reported to
have beneficial effects on atherogenesis, although only few
studies on humans are available [14e16]. One of the few
available studies is a recent paper by Tricon et al. that
examined the effect of naturally enriched dairy products
with cis-9, trans-11 CLA on blood profile of healthy middle-
aged men [16].
The present dietary intervention study was conducted in
order to evaluate the effects of diet containing a cis-9,
trans-11 CLA-rich cheese on different parameters,
including lipid parameters, so reflecting the complex
pathophysiology of atherothrombotic diseases. However,
similar to Tricon et al. [16], who reported no effects of such
dairy product on lipid parameters, we were not able to
report any significant effects of the test cheese on lipid
parameters. To date, the effects on lipid metabolism of cis-
9, trans-11 CLA are still objects of concern. LDL-cholesterol
appears to be significantly reduced by this particular isomer
of CLA [15]. Conversely, triglycerides did not significantly
change or decrease compared to placebo in some studies
with CLA supplementation [16]. Similarly, the effect of CLA
supplementation on HDL-cholesterol is unclear. Some
studies have shown a decrease in HDL-cholesterol with
mixed isomer CLA supplementation, one study found an
increase in HDL-cholesterol [14], and others reported no
effect [15,17]. In another study that examined the effect of
supplementation with the individual isomer cis-9, trans-11,
no effect on HDL-cholesterol was observed after 8 week of
supplementation [4]. Thus, it appears that the effects of
this particular isoform of CLA on lipid profile need to be
further examined to assess the atherogenic potential of CLA
supplementation in humans.
Table 4 Effect of dietary interventions with CLA-rich and control dairy products on inflammatory profile
Variable Test period Control period pa
Interleukin-6, pg/mL
Before 8.08 1.57 6.07 1.55
After 4.58 0.94 6.64 1.56
p (beforeeafter) 0.015 0.8
Change 3.49 (6.08; 0.91) 0.57 (5.97; 7.11) 0.036
Interleukin-8, pg/mL
Before 45.02 5.82 31.37 5.58
After 28.59 2.64 27.42 4.62
p (beforeeafter) 0.012 0.3
Change 16.42 (28; 4.84) 3.95 (12.13; 4.24) 0.021
TNF-a, pg/mL
Before 53.58 25.67 21.22 11.86
After 32.09 17.42 18.64 9.58
p (beforeeafter) 0.049 0.4
Change 21.48 (42.89; 0.06) 2.59 (10.95; 5.78) 0.018
VEGF, pg/mL
Before 959.24 114.36 901.99 242.30
After 842.42 566.79 601.41 157.25
p (beforeeafter) 0.5 0.09
Change 116.81 (485.81; 252.18) 300.59 (672.49; 71.31) 0.07
Interleukin-10, pg/mL
Before 19.75 6.63 10.84 3.78
After 11.41 2.79 7.16 1.88
p (beforeeafter) 0.3 0.3
Change 8.34 (27.27; 10.59) 3.68 (11.40; 4.05) 0.8
Interleukin-12, pg/mL
Before 49.5 27.93 15.75 4.19
After 25.76 9.66 22.13 16.81
p (beforeeafter) 0.3 0.06
Change 23.75 (32.88; 80.37) 6.38 (27.73; 40.49) 0.9
TNF, Tumour Necrosis Factor; VEGF, Vascular Endothelial Growth Factor.
General linear model adjusted for age, and gender; values are expressed as geometric mean SD.
a Comparison between absolute changes induced by the 2 diets (Wilcoxon signed-ranks test).
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A striking evidence of our study is, on the other hand,
the significant effect of cis-9, trans-11 CLA cheese on
inflammatory, haemorheological and platelet aggregation
profiles, by possibly hypothesising a beneficial role of this
particular isoform of CLA on these pathophysiological
processes. CLAs have been previously reported to attenuate
inflammatory cytokine expression in animals and humans
[18], and it has been recently reported that they are able to
inhibit the expression of cytokine-induced adhesion mole-
cules on endothelial and smooth muscle cells [19]. Thus, it
is conceivable to hypothesise that CLAs are able to atten-
uate the atherosclerotic process through inhibition of the
initiating inflammatory cytokines, such as those measured
in our study, as well as through inhibition of the stress
signalling cascades these cytokines elicit. On the other
hand, it must be noted that a recent study conducted in
postmenopausal women reported no significant effects of
an oil mixture with cis-9, trans-11 CLA on inflammatory
markers, as compared with olive oil [17].
Another important finding of the study is the significant
improvement of red cell deformability obtained in the
group of subjects consuming the test cheese in comparison
with those consuming the commercial cheese. Actually, red
cell deformability was reported to be significantly influ-
enced by omega-3 polyunsaturated fatty acids; we have
indeed recently observed a beneficial effect of fish eating
on these specific risk markers [20]. On the other hand, CLAs
from ruminant animals and omega-3 polyunsaturated fatty
acids from fish oil share some striking effects on cell
functions, on animal models of specific diseases as well as
on human health [4]. These include beneficial effects in
inhibiting cancer cell proliferation, anti-tumour effects in
animal models of cancer, anti-inflammatory effects on
cells, in animal models and humans, and more recently for
CLAs, beneficial effects in cardiovascular disease preven-
tion. Hence, possible similar effects of CLAs on red blood
cells can be hypothesised. On the other hand, Wahle et al.
recently suggested a hypothesis of the link between these
CLA and omega-3 polyunsaturated fatty acids [1]. There-
fore, the findings observed in our crossover intervention
study, where a consumption of a cheese naturally rich in
CLAs demonstrated to have a beneficial effect on circu-
lating levels of some atherosclerotic risk markers, like
omega-3 polyunsaturated fatty acids have, seem to
Table 5 Effect of dietary interventions with CLA-rich and control dairy products on haemorheological profile
Variable Test period Control period pa
Red blood
cells, 1012/L
Before 4.58 0.12 4.77 0.16
After 4.66 0.16 4.74 0.15
p (beforeeafter) 0.4 0.6
Change 0.08 (0.12; 0.28) 0.04 (0.16; 0.11) 0.21
Hematocrit, %
Before 40.8 0.95 41.4 0.98
After 40.9 1.03 41.2 0.90
p (beforeeafter) 0.9 0.5
Change 0.1 (1.9; 2.2) 0.2 (1.5; 0.9) 0.42
WBV 94.500 s1, mPa s
Before 4.24 0.04 4.26 0.05
After 4.26 0.03 4.20 0.10
p (beforeeafter) 0.8 0.4
Change 0.02 (0.006; 0.82) 0.06 (0.34; 0.17) 0.34
WBV 0.512 s1, mPa s
Before 23.77 0.35 22.86 0.80
After 24.33 0.78 22.16 0.93
p (beforeeafter) 0.5 0.3
Change 0.56 (1.13; 2.25) 0.70 (2.45; 1.05) 0.41
EF, %
Before 7.61 0.71 9.64 0.44
After 9.12 0.97 9.41 0.55
p (beforeeafter) 0.027 0.7
Change 1.51 (0.23; 2.29) 0.22 (2.14; 1.69) 0.027
PLV, mPa s
Before 1.33 0.01 1.32 0.04
After 1.31 0.02 1.36 0.03
p (beforeeafter) 0.1 0.09
Change 0.02 (0.04; 0.06) 0.04 (0.01; 0.09) 0.03
WBV, Whole blood viscosity; EF, Erythrocyte filtration; PLV, Plasma viscosity.
General linear model adjusted for age, and gender; values are expressed as mean SD.
a Comparison between absolute changes induced by the 2 diets (Wilcoxon signed-ranks test).
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hypothesise a mechanism for CLA similar to that reported
for omega-3 compounds.
Interestingly, in our limited study population we were
able to report significant reduced levels of aggregation
induced by arachidonic acid after the consumption of test
cheese. The role of platelets and platelet aggregation on
the occurrence of atherothrombotic diseases is well known
for decades, and the clinical significance of a high level of
aggregation on the risk profile of the general population is
of arousing interest [21]. In the present study, we observed
a significant reduction of platelet aggregation induced by
arachidonic acid in our population of clinically healthy
subjects, after the intervention period with the test
cheese. The beneficial effects observed by this particular
type of fatty acid can be possibly linked to the common
pathways between CLAs and arachidonic acid for the
cyclooxygenase reaction and for the synthesis of prosta-
glandins. Therefore, it is likely to suggest a possible bene-
ficial role of this particular type of fatty acids on the
synthesis of arachidonic acid, and, consequently, on the
biochemical processes related to arachidonic acid such as
platelet aggregation.
Our study has several main limitations. An important
limitation is the restricted sample size of the study. Further
and larger studies need to be conducted before drawing any
firm conclusion on the effects of such food products on
human health. The results of the present study are just
a promising basis for evaluating more completely this
aspect of clinical nutrition.
Another limitation is the lack of assessment of dietary
habits and physical activity in our study population. The
possibility that changes in dietary and/or lifestyle habits
have significantly affected parameters investigated cannot
be excluded, although, before initiating, all subjects were
instructed by physicians and by an expert dietician to
maintain their usual lifestyle habits.
Finally, another possible limitation is that a proportion
of our samples’ subjects were active smokers at the time of
enrolment. Cigarette smoking may significantly influence
some of the investigated parameters, such as inflammatory
variables.
In conclusion, we observed beneficial effects of cis-9,
trans-11 CLA-rich ewe cheese consumption on several risk
parameters for atherosclerotic cardiovascular disease.
These observations, although preliminary and obtained
in a limited study group, seem to be of relevance for the
practical implications in terms of nutrition and health of
the general population. If the effects of dairy products
naturally enriched for their contents of cis-9, trans-11 CLA
are confirmed by further examinations, this will likely have
important implications for human nutrition and food
industry.
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Table 6 Adjusted values for platelet function’s parameters
Variable Test period Control period pa
Aggregation ADP 2 mmol, %
Before 79.7 2.60 78.3 5.69
After 81.7 2.32 83.5 4.50
p (beforeeafter) 0.7 0.2
Change 2 (8.99; 12.99) 5.25 (5; 15.50) 0.7
Aggregation ADP 10 mmol, %
Before 85.4 1.66 90.38 1.06
After 84.6 3.67 91.75 3.03
p (beforeeafter) 0.9 0.7
Change 0.8 (10.64; 9.04) 1.38 (6.15; 8.89) 0.6
Aggregation collagen, %
Before 81.2 1.71 82.63 10.09
After 82 3.41 89.88 2.93
p (beforeeafter) 0.8 0.5
Change 0.8 (10.18; 8.58) 7.25 (17.48; 31.98) 0.6
Aggregation arachidonic, %
Before 87.8 1.76 83.1 3.22
After 77.7 3.56 88.8 0.78
p (beforeeafter) 0.045 0.09
Change 10.1 (19.91; 0.29) 5.62 (1.17; 12.42) 0.02
ADP, Adenosine diphosphate.
General linear model adjusted for age, and gender; values are expressed as mean SD.
a Comparison between absolute changes induced by the 2 diets (Wilcoxon signed-ranks test).
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